PFAS Transfer to Placenta & Fetus: Timing & Levels During Pregnancy

Exposure to per- and polyfluoroalkyl substances (PFAS) during pregnancy is linked to impacts on placental health and fetal development, with the timing of exposure appearing critical, according to recent research. A study published in January 2025 in Environmental International and further investigations detailed in publications from September 2021 and January 30, 2025, highlights the complex relationship between maternal PFAS levels, placental function, and fetal exposure.

Transplacental Transfer Varies by PFAS Type and Trimester

Research confirms that PFAS cross the placental barrier, leading to prenatal exposure of the fetus. However, the efficiency of this transfer isn’t uniform across all PFAS compounds, nor is it consistent throughout pregnancy. A study published in February 2025 in Nature, examining a cohort primarily exposed to PFAS-contaminated drinking water between 2015 and 2020, found varying transplacental transfer efficiencies (TTEs). Perfluorohexane sulfonic acid (PFHxS) exhibited the highest TTE, with a median of 0.68, while the n-PFOS isomer showed the lowest, at 0.33. This suggests some PFAS compounds are more readily transferred to the fetus than others.

Importantly, the TTE increases linearly across trimesters, indicating greater transfer efficiency as pregnancy progresses. The January 2025 study in Environmental International found that early-to-mid gestation, particularly the second trimester, yielded the strongest indicators of placental and cord serum PFAS levels, with the exception of PFOA, which was best reflected by third trimester or placental levels. This timing is crucial for understanding potential windows of vulnerability during fetal development.

Placental Function and PFAS Exposure

The January 2025 research in Environmental International investigated the impact of PFAS on placental function, specifically examining placental weight, vascular perfusion, and signs of placental aging. The study, involving 367 pregnant women, revealed associations between specific PFAS and placental parameters. Quantification of PFHxPA was associated with an increase in villi with syncytial knots (a marker of potential placental stress) and reduced intervillous spaces. Similar patterns were observed with PFHpA. Increases in placental weight were observed in women with lower PFAS exposure.

The research also employed cluster analysis, identifying a moderate-to-higher PFAS exposure group that exhibited, on average, lower placental weight compared to those with lower exposure. These findings suggest that PFAS exposure may disrupt normal placental development, and function.

Specific PFAS Compounds and Their Effects

The studies pinpointed several PFAS compounds of particular concern. PFHxS and PFOS consistently emerged as significant predictors of both placental and cord serum levels. Stochastic intervention modeling identified T1 PFNA and PFDA, T2 PFOS, PFOA, PFHxS, and PFNA, and T3 PFHxS as robust predictors of placental levels. For cord levels, T1 PFOS and PFHxS, T2 PFOS and PFNA, T3 PFOA, and placental PFOA were identified as important predictors.

The research highlights the importance of considering individual PFAS compounds rather than treating them as a homogenous group. The varying TTEs and associations with placental parameters underscore the need for targeted research and potential regulatory strategies.

Implications for Fetal and Child Health

The transfer of PFAS to the fetus has been linked to adverse health outcomes in children, including lower birth weight and immunological effects. Limited evidence also suggests potential neurodevelopmental effects. The January 2025 study in Environmental International builds on previous research demonstrating these associations, providing further insight into the mechanisms by which PFAS may impact fetal development.

The findings emphasize the importance of understanding the timing and extent of PFAS exposure during pregnancy. The identification of specific PFAS compounds and trimesters associated with greater placental transfer efficiency can inform risk assessments and potentially guide interventions to minimize fetal exposure. Further research is needed to fully elucidate the long-term health consequences of prenatal PFAS exposure and to assess the potential risks associated with less well-studied PFAS compounds.

The transplacental transfer efficiency (TTE) of PFAS is dependent on chain length and functional group, according to a meta-analysis published in October 2021. This underscores the complexity of PFAS behavior and the need for comprehensive data on a wider range of compounds to accurately assess fetal exposure risks.